Kevin J. Curran

17.1k total citations · 2 hit papers
94 papers, 5.3k citations indexed

About

Kevin J. Curran is a scholar working on Oncology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Kevin J. Curran has authored 94 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 28 papers in Molecular Biology and 23 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Kevin J. Curran's work include CAR-T cell therapy research (48 papers), Acute Lymphoblastic Leukemia research (23 papers) and Virus-based gene therapy research (16 papers). Kevin J. Curran is often cited by papers focused on CAR-T cell therapy research (48 papers), Acute Lymphoblastic Leukemia research (23 papers) and Virus-based gene therapy research (16 papers). Kevin J. Curran collaborates with scholars based in United States, Netherlands and Canada. Kevin J. Curran's co-authors include Renier J. Brentjens, Challice L. Bonifant, Jae H. Park, Michel Sadelain, Xiuyan Wang, Isabelle Rivière, Marco L. Davila, Craig S. Sauter, Mithat Gönen and Brigitte Sénéchal and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Kevin J. Curran

89 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

2018 1.8k citations Jae H. Park, Isabelle Rivière et al. profile →
Toxicity and management in CAR T-cell therapy

2016 661 citations Renier J. Brentjens, Kevin J. Curran et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin J. Curran United States	32	3.6k	1.9k	1.3k	1.1k	973	94	5.3k
Niels W.C.J. van de Donk Netherlands	50	5.1k 1.4×	3.7k 1.9×	2.2k 1.7×	342 0.3×	439 0.5×	267	8.9k
Paul J. Neeson Australia	33	2.4k 0.7×	1.4k 0.7×	1.9k 1.5×	428 0.4×	467 0.5×	144	4.2k
Roger A. Greenberg United States	51	2.6k 0.7×	7.9k 4.1×	1.2k 1.0×	1.2k 1.2×	160 0.2×	98	10.3k
Junko Murai Japan	35	4.2k 1.2×	4.5k 2.3×	428 0.3×	471 0.4×	125 0.1×	76	6.0k
Andrea Schietinger United States	25	3.1k 0.9×	1.2k 0.6×	3.5k 2.7×	352 0.3×	275 0.3×	41	5.1k
Nathalie Scholler United States	31	1.5k 0.4×	1.1k 0.6×	1.1k 0.9×	400 0.4×	585 0.6×	73	3.5k
Alison L. Hannah United States	31	2.5k 0.7×	2.5k 1.3×	440 0.3×	665 0.6×	76 0.1×	122	4.9k
Mary Philip United States	22	2.7k 0.8×	1.2k 0.6×	3.0k 2.3×	241 0.2×	210 0.2×	64	4.9k
Jamil Momand United States	25	6.3k 1.8×	6.0k 3.1×	413 0.3×	642 0.6×	172 0.2×	40	9.2k
Nicole M. Haynes Australia	31	2.3k 0.7×	1.1k 0.6×	2.6k 2.0×	518 0.5×	386 0.4×	58	4.2k

Countries citing papers authored by Kevin J. Curran

Since Specialization

Citations

This map shows the geographic impact of Kevin J. Curran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin J. Curran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin J. Curran more than expected).

Fields of papers citing papers by Kevin J. Curran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin J. Curran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin J. Curran. The network helps show where Kevin J. Curran may publish in the future.

Co-authorship network of co-authors of Kevin J. Curran

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin J. Curran. A scholar is included among the top collaborators of Kevin J. Curran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin J. Curran. Kevin J. Curran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

John, Samuel, Kevin J. Curran, Amy K. Keating, et al.. (2025). Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Advances. 9(20). 5249–5262.

Admiraal, Rick, Stefan Nierkens, Marc Bierings, et al.. (2025). Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation. Blood Advances. 9(9). 2344–2353. 1 indexed citations

Major-Monfried, Hannah, Neerav Shukla, Andromachi Scaradavou, et al.. (2023). Donor Derived Leukemia in a Recipient of Allogeneic Hematopoietic Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa. Transplantation and Cellular Therapy. 29(2). S367–S368.

Klein, Elizabeth, Audrey Mauguen, Jaap Jan Boelens, et al.. (2023). T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment of Fanconi anemia and MDS/AML. Bone Marrow Transplantation. 59(1). 23–33. 1 indexed citations

Boelens, Jaap Jan, Susan E. Prockop, Kevin J. Curran, et al.. (2023). Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients. Frontiers in Oncology. 13. 1221782–1221782. 5 indexed citations

John, Samuel, Michael Heim, Kevin J. Curran, et al.. (2023). Improved Relapse-Free Survival (RFS) for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Low or Intermediate Preinfusion Disease Burden Treated with Tisagenlecleucel: Results from the CIBMTR Registry. Transplantation and Cellular Therapy. 29(2). S37–S38. 1 indexed citations

Fraint, Ellen, Elizabeth Klein, Audrey Mauguen, et al.. (2022). Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(1). 46.e1–46.e6. 5 indexed citations

Minard‐Colin, Véronique, Birgit Burkhardt, Shannon L. Maude, et al.. (2019). BIANCA: A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA. Hematological Oncology. 37(S2). 558–559. 1 indexed citations

Cooper, Cynthia D., et al.. (2018). Protein Kinase A Signaling Inhibits Iridophore Differentiation in Zebrafish. Journal of Developmental Biology. 6(4). 23–23. 3 indexed citations

10.

Gulati, Nitya, Farid Boulad, Maria Cancio, et al.. (2017). Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma. Blood. 130. 5172–5172. 1 indexed citations

11.

Curran, Kevin J., Steven Margossian, Nancy A. Kernan, et al.. (2017). High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL. Blood. 130. 1326–1326. 1 indexed citations

12.

Curran, Kevin J., Lewis B. Silverman, Rachel Kobos, et al.. (2016). Abstract IA07: Chimeric antigen receptor T cells for cancer immunotherapy. Cancer Research. 76(5_Supplement). IA07–IA07. 4 indexed citations

13.

Suzuki, Maya, Kevin J. Curran, & Nai‐Kong V. Cheung. (2015). Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatric Blood & Cancer. 62(8). 1326–1336. 9 indexed citations

14.

Park, Jae H., Isabelle Rivière, Xiuyan Wang, et al.. (2014). CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL. Blood. 124(21). 382–382. 17 indexed citations

15.

Yu, Ker, Celine Shi, Lourdes Toral‐Barza, et al.. (2010). Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2. Cancer Research. 70(2). 621–631. 162 indexed citations

16.

Verheijen, Jeroen C., David J. Richard, Kevin J. Curran, et al.. (2010). 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability. Bioorganic & Medicinal Chemistry Letters. 20(8). 2648–2653. 22 indexed citations

17.

Yu, Ker, Lourdes Toral‐Barza, Celine Shi, et al.. (2009). Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin. Cancer Research. 69(15). 6232–6240. 277 indexed citations

18.

Richard, David J., Jeroen C. Verheijen, Kevin J. Curran, et al.. (2009). Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability. Bioorganic & Medicinal Chemistry Letters. 19(24). 6830–6835. 42 indexed citations

19.

Boffa, Daniel J., Dolca Thomas, Kevin J. Curran, et al.. (2005). Measurement of Apoptosis of Intact Human Islets by Confocal Optical Sectioning and Stereologic Analysis of YO-PRO-1???Stained Islets. Transplantation. 79(7). 842–845. 23 indexed citations

20.

Visalli, Robert J., Martin J. Di Grandi, Jonathan D. Bloom, et al.. (2004). Thiourea Inhibitors of Herpesviruses Part 3: Inhibitors of VZV. Bioorganic & Medicinal Chemistry Letters. 14(16). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact